logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
返回期刊详情
I

Immunotherapy

IF2.3
论文数109
被引数
期刊论文 109
发表时间
delete
The potential of PDHA1 as a cuproptosis-related prognostic and immune biomarker in lung squamous cell carcinomaPDHA1作为肺癌鳞状细胞癌中铜死亡相关预后和免疫生物标志物的潜力
deleteImmunotherapy
IF2.3
delete2026-10-27
delete0
PREAI
deleteShaopeng Zheng; Zixun Huang; Geng Wang; Jiajia Chen; Shubin Guan; Zhen Chen; Mingdong Wang; Mingzhi Wang; Zhong Huang
delete分享
delete收藏
Real-world efficacy and safety of neoadjuvant immunochemotherapy in patients with triple-negative breast cancer新辅助免疫化疗在 triple-negative breast cancer 患者中的真实世界疗效与安全性
deleteImmunotherapy
IF2.3
delete2026-10-10
delete0
PREAI
deleteRuoxi Xu; Pinchao Fan; Yiqiu Liu; Chengjun Zhu; Dandan Wang; Fang Yang; Xiaoxiang Guan
delete分享
delete收藏
Circulating and tumor microenvironment immunomarkers associate with immunotherapy efficacy in advanced bladder urothelial carcinoma: an exploratory multicenter study integrating genomic and immunophenotypic profiling循环和肿瘤微环境免疫标志物与晚期膀胱尿路上皮癌免疫治疗疗效相关：一项整合基因组学和免疫表型分型的探索性多中心研究
deleteImmunotherapy
IF2.3
delete2026-10-09
delete0
PREAI
deleteSha Liu; Junjun Lu; Zhaojie Lyu; Zhengmao Lu; Yunmei Liu; Ruiying Zhang; Wentao Xu; Guoping Sun; Yingying Du; Lei Huang
delete分享
delete收藏
Association of early dynamic changes in peripheral blood immune-inflammatory indices with subsequent acquired resistance to immune checkpoint inhibitors in advanced non-small cell lung cancer: a landmark analysis外周血免疫炎症指标早期动态变化与晚期非小细胞肺癌患者后续获得性免疫检查点抑制剂耐药的相关性：一项里程碑分析
deleteImmunotherapy
IF2.3
delete2026-10-08
delete0
PREAI
deleteLin Song; Wanghui Lv; Qingbo Wang; Yan Luo
delete分享
delete收藏
Efgartigimod in the treatment of severe Guillain–Barre syndrome with overlapping autoantibody syndrome: a case report and updated clinical reviewEfgartigimod在治疗重叠自身抗体综合征的重症吉兰-巴雷综合征中的应用：病例报告及临床综述更新
deleteImmunotherapy
IF2.3
delete2026-10-08
delete0
PREAI
deleteYueqi Wang; Siqi Wang; Huijuan Fan; Wenjun Sun; Yanmei Fa; Yuxian Yang; Ronghua Chen; Kang Du; Shanshan Wu
delete分享
delete收藏
Liquid–liquid phase separation-related gene can predict prognosis and influence immune microenvironment in acute myeloid leukemia液-液相分离相关基因可预测急性髓系白血病的预后并影响免疫微环境
deleteImmunotherapy
IF2.3
delete2026-10-08
delete0
PREAI
deleteXiaoyue Ren; Lijie Zhang; Linli Zhou; Shuqi Zhao
delete分享
delete收藏
Cost-effectiveness analysis of penpulimab plus anlotinib versus sorafenib as first-line therapy for advanced hepatocellular carcinoma帕博利珠单抗联合安罗替尼与索拉非尼作为晚期肝细胞癌一线治疗的经济性分析
deleteImmunotherapy
IF2.3
delete2026-10-04
delete0
PREAI
deleteZhiwei Zheng; Lisheng Huang; Yuling Zhang; Huide Zhu; Ling Fang
delete分享
delete收藏
Real-world utilization of immune checkpoint inhibitors in medicare-eligible patients with triple-negative breast cancer in the United States美国医疗保险资格患者中三阴性乳腺癌免疫检查点抑制剂的实际情况应用
deleteImmunotherapy
IF2.3
delete2026-10-04
delete0
deleteOAAI
deleteXiaohan Hu; Amin Haiderali; Yezhou Sun; Wilbur Pan
delete分享
delete收藏
Beyond PD-L1: emerging clinical and molecular biomarkers of response to immune checkpoint inhibitors in non-small cell lung cancer超越PD-L1：非小细胞肺癌对免疫检查点抑制剂反应的临床与分子生物标志物的新进展
deleteImmunotherapy
IF2.3
delete2026-10-01
delete0
PREAI
deleteCalogera Claudia Spagnolo; Irene Campo; Elena Fassi; Francesco Nucera; Paolo Ruggeri; Paola Muscolino; Carla Infurna; Antonio Ieni; Vanesa Gregorc; Chiara Lazzari; Mariacarmela Santarpia
delete分享
delete收藏
Addressing socioeconomic barriers to immunotherapy access for non-small cell lung cancer in Japan解决日本非小细胞肺癌免疫疗法获取的社会经济障碍
deleteImmunotherapy
IF2.3
delete2026-09-22
delete0
deleteOAAI
deleteHiroe Suzuki-Chiba; Atsushi Miyawaki
delete分享
delete收藏
Efficacy and safety of chimeric antigen receptor T-cell therapy in primary central nervous system lymphoma: a systematic review and meta-analysis嵌合抗原受体T细胞疗法在原发性中枢神经系统淋巴瘤中的有效性和安全性：一项系统评价和荟萃分析
deleteImmunotherapy
IF2.3
delete2026-09-16
delete0
deleteOAAI
deleteAbdulrahman F. Al-Mashdali; Mujahid O. Abdelraof; Rasha Kaddoura; Azza M. Halfawi; Mohamed Elfatih M. Yousif; Mohammed Abdulgayoom; Abdul Rashid Shah; Shehab F. Mohamed
delete分享
delete收藏
From receptor biology to therapy: importance of different EGFR mutations in the development of targeted cancer therapies从受体生物学到疗法：不同EGFR突变在靶向癌症疗法发展中的重要性
deleteImmunotherapy
IF2.3
delete2026-09-15
delete0
PREAI
deleteU Krishnaja; Neethu J; Maitheli Sarkar; Krishnakumar N. Menon; Bhargab Kalita
delete分享
delete收藏
In vivo CAR-T for solid tumors: facing all the challenges of ex vivo CAR-T and more体内CAR-T治疗实体瘤：面临体外CAR-T的所有挑战及更多挑战
deleteImmunotherapy
IF2.3
delete2026-09-08
delete0
PREAI
deleteYulong Xia; Jintian Song; Jiong Wu
delete分享
delete收藏
Bromodomain inhibitors in autoimmune diseases溴结构域抑制剂在自身免疫性疾病中的应用
deleteImmunotherapy
IF2.3
delete2026-09-06
delete0
PREAI
deleteMarcin Szczepanik; Wojciech Pociej; Joanna Kulpa; Jakub Senko; Oliwia Jerzyńska; Andrzej Pawlik
delete分享
delete收藏
Cancer vaccines as targeted therapies: translational advances and challenges癌症疫苗作为靶向治疗：转化进展与挑战
deleteImmunotherapy
IF2.3
delete2026-09-05
delete0
PREAI
deleteZahra Shafaghat; Maryam Sadri; Mona Roozbehani; Fatemeh Kheiri; Maryam Dorfaki; Fatemeh Faraji
delete分享
delete收藏
Prognostic factors in avelumab maintenance therapy for metastatic urothelial carcinomaavelumab维持治疗转移性尿路上皮癌的预后因素
deleteImmunotherapy
IF2.3
delete2026-09-02
delete0
PREAI
deleteCaner Kapar; Oğuzcan Özkan; Eda Eylemer Mocan; Sendag Yaslikaya; Ali Murat Tatlı; Goncagül Akdağ; Hacer Demir; Irem Bilgetekin; Kaan Helvacı; Fatih Selcukbiricik; Fatih Köse; Murat Sari; Gökmen Umut Erdem; Zehra Sucuoğlu İşleyen; Cagatay Arslan; Sinemis Celik; Türkkan Evrensel; Bekir Mert Durukan; Seher Nazli Kazaz; Banu Ozturk; Halil Çelik; Miraç Özen; Pınar Erel; Pervin Can Şancı; Yakup Ergün; Hakan Taban; Ömer Faruk Kuzu; Burcu Ulaş Kahya; Ahmet Melih Arslan; Abdullah Sakin; Murat Araz; Kerem Okutur; Fahri Akgül; Cem Mirili; Alper Sevinç; Fatih Atalah; Yakup Düzköprü; Burcu Gülbağcı; Nurten Kandemir; Hakan Kosku; Esra Aydın; Dilek Erdem; Murad Guliyev; Mesut Yılmaz; Yaşar Çulha; Berksoy Şahin; Pınar Gürsoy; Mustafa Erman; Yüksel Ürün; Deniz Tural
delete分享
delete收藏
Efficacy of PARP inhibitor and immune checkpoint inhibitor combination therapy in PD-L1–negative cancers: a systematic review and meta-analysisPD-L1阴性癌症中PARP抑制剂与免疫检查点抑制剂的联合治疗效果：系统评价与荟萃分析
deleteImmunotherapy
IF2.3
delete2026-08-25
delete0
PREAI
deleteSusu Zhou; Vishw Patel; Noriko Kishi; Komal Akhtar; Che-Kai Tsao
delete分享
delete收藏
Low-dose interleukin-2 combined with thalidomide for a severe cutaneous immune-related adverse event associated with PD-1/CTLA-4 bispecific antibody therapy: a case report低剂量白细胞介素-2联合沙利度胺治疗与PD-1/CTLA-4双特异性抗体疗法相关的严重皮肤免疫相关不良事件：病例报告
deleteImmunotherapy
IF2.3
delete2026-08-25
delete0
PREAI
deleteZhiqiang Li; Yufei Li; Yuhan Zhang; Qiuxia Ye; Jing He; Mingwei Li
delete分享
delete收藏
Impact of immunotherapy in the treatment of early-stage non-small lung cancer, melanoma, and colorectal cancer免疫疗法在早期非小细胞肺癌、黑色素瘤和结直肠癌治疗中的影响
deleteImmunotherapy
IF2.3
delete2026-08-24
delete0
PREAI
deleteAlfredo Tartarone; Raffaele Conca; Alessandra Perrone; Rosa Lerose
delete分享
delete收藏
Injection-based safety of aqueous venom immunotherapy during venom extract shortage: impact of forced depot-to-aqueous switching基于注射的安全性与水剂抗蛇毒免疫疗法在抗蛇毒提取剂短缺期间的影响：强制 depot-to-aqueous 转换的影响
deleteImmunotherapy
IF2.3
delete2026-08-24
delete0
PREAI
deleteGökten Bulut; Rukiye Demiralp; Şefika Karabaş; Fidan Coşkun
delete分享
delete收藏